Screener
Kymera Therapeutics KYMR Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total other income: | 14,396 | 7,943 | 29,318 | 16,788 |
| Net loss | $(61,211) | $(76,614) | $(130,445) | $(142,195) |
| Other comprehensive loss: | ||||
| Unrealized (loss) gain on marketable securities | (2,963) | 337 | (8,957) | 1,764 |
| Total comprehensive loss | $(64,174) | $(76,277) | $(139,402) | $(140,431) |
| Net loss | $(61,211) | $(76,614) | $(130,445) | $(142,195) |
| Net loss per share, basic and diluted | $(0.62) | $(0.95) | $(1.33) | $(1.77) |
| Weighted average common stock outstanding, basic and diluted | 98,177,158 | 80,449,405 | 97,857,489 | 80,298,940 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Kymera Therapeutics (KYMR) reported comprehensive income (loss), net of tax, attributable to parent of -$64.17M in Q2 2026.
- How has Kymera Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Kymera Therapeutics's comprehensive income (loss), net of tax, attributable to parent increased by 15.9% year-over-year, from -$76.28M to -$64.17M.
- What is the long-term trend for Kymera Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Kymera Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 32.2% compound annual growth rate (CAGR), from -$100.75M to -$308.07M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity during a period resulting from transactions and other events from non-owner sources, including net income and other comprehensive income items like unrealized gains or losses on securities and foreign currency translation adjustments. It provides a more holistic view of the company's financial performance by capturing volatility that is excluded from traditional net income. Investors use this to evaluate the broader impact of market fluctuations and accounting adjustments on the company's total equity position.
Ask your AI about Kymera Therapeutics's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude